Short answer
Oric Pharmaceuticals, Inc. (ORIC) filed its Q2 2026 10-Q quarterly report on Aug 3, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$41M
- −14.1% YoY · −16.0% QoQ
- EPS (diluted)
- −$0.38
- +19.1% YoY · −11.8% QoQ
Source: XBRL data from the Oric Pharmaceuticals, Inc. (ORIC) Q2 2026 10-Q on SEC EDGAR. USD.
Oric Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No revenue generated in Q2 2026 or comparable Q2 2025
- Net loss $41.5M vs $36.4M YoY
- R&D expense $36.3M vs $30.5M, led by rinzimetostat costs $16.0M vs $7.3M
- Operating cash outflow $64.0M through June 2026 vs $63.4M YoY
- ATM proceeds $59.9M through June; cash expected to fund operations into second half of 2028
Risk Factors
- No explicit new or changed risk factors disclosed versus the most recent 10-K
- Cash, cash equivalents and investments $387.6M at June 30, 2026, funding operations into second half of 2028
- Regulatory approval uncertainty: FDA Project Optimus may alter oncology dose-selection requirements during development
- Clinical-stage dependence: rinzimetostat and enozertinib require additional trials, manufacturing expansion and regulatory approval
- Financial losses: $77.3M net loss for six months ended June 30, 2026, with accumulated deficit of $769.5M
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Oric Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.